All In Biotech

NDA 217389 · Msd

Ohtuvayre

Ensifentrine · Inhalation · Phosphodiesterase 3 Inhibitor; Phosphodiesterase 4 Inhibitor

Novel

CDER novel approval, Jun 26, 2024: To treat chronic obstructive pulmonary disease

Last checked: Nov 20, 2026Latest source record: Jun 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Jun 26, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

21

5 Phase 3, 2 recruiting

FAERS reports

1,830

635 serious, 73 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 13, 2026.

OHTUVAYRE is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. OHTUVAYRE is a phosphodiesterase 3 (PDE3) inhibitor and phosphodiesterase 4 (PDE4) inhibitor indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. ( 1 )

Mechanism: Ensifentrine is a small molecule that is an inhibitor of the PDE3 and PDE4 enzymes. PDE3 primarily hydrolyzes the second-messenger molecule cyclic adenosine monophosphate (cAMP) but is also capable of hydrolyzing cyclic guanosine monophosphate (cGMP). PDE4 hydrolyzes cAMP only. Inhibition of PDE3 and PDE4 results in accumulation of intracellular levels of cAMP and/or cGMP, resulting in various downstream signaling effects.

Therapeutic areas: Respiratory

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 26, 2024 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
  • OHTUVAYRE · ENSIFENTRINE 3MG/2.5ML · SUSPENSION, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ensifentrine" as an intervention, any sponsor and status, largest first.

All 21 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea376
  • drug ineffective132
  • chronic obstructive pulmonary disease129
  • diarrhoea106
  • cough99
  • back pain98
  • pneumonia94
  • product dose omission issue91
  • no adverse event83
  • death82
  • headache75
  • chest discomfort63

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20202
20215
20223
20232
202427
2025783
20261,008

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ohtuvayre (Ensifentrine)

2024 spending

$113K

Beneficiaries

25

40 claims

Per beneficiary

$4,538

$18.91 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$113,443

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 16 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.